2-(2-二氟甲基苯基)-4,4,5,5-四甲基-1,3,2-二氧硼烷 | 879275-70-4

• 物质功能分类: 有机原料 - 烃类化合物及其衍生物 - 芳香烃
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(2-二氟甲基苯基)-4,4,5,5-四甲基-1,3,2-二氧硼烷
• 中文别名: 2-二氟甲基-苯硼酸
• 英文名称: (2-(difluoromethyl)phenyl)boronic acid
• 英文别名: [2-(difluoromethyl)phenyl]boronic acid
• CAS: 879275-70-4
• 化学式: C₇H₇BF₂O₂
• 分子量: 171.939
• InChiKey: RTUHFDBTYFIWMU-UHFFFAOYSA-N

物化性质

• 沸点：
  301.1±52.0 °C(Predicted)
• 密度：
  1.27±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  4

制备方法与用途

概述

2-(2-二氟甲基苯基)-4,4,5,5-四甲基-1,3,2-二氧硼烷是一种有机中间体，常用于金属催化的偶联反应。

应用

2-(2-二氟甲基苯基)-4,4,5,5-四甲基-1,3,2-二氧硼烷可用于合成化合物6-氨基-N-（5-氯-6-（2-（二氟甲基）苯基）吡啶-2-基）吡啶-2-磺酰胺。

反应信息

• 作为反应物：
  描述：

  2-(2-二氟甲基苯基)-4,4,5,5-四甲基-1,3,2-二氧硼烷 生成 2-(2-(difluoromethyl)phenyl)thiazole-4-carboxylic acid
  参考文献：
  名称：

  CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE

  摘要：

  公式I的环醚吡唑-4-基-杂环基-羧酰胺化合物，包括立体异构体、几何异构体、互变异构体和其药学上可接受的盐，其中R2为环醚，X为噻唑基、吡啶基、吡啶基或嘧啶基，可用于抑制Pim激酶，并用于治疗由Pim激酶介导的癌症等疾病。公开了使用公式I化合物进行体外、体内和体内诊断、预防或治疗哺乳动物细胞中的这类疾病或相关病理条件的方法。

  公开号：

  US20140088117A1

文献信息

• SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
  申请人：OOST Thorsten

  公开号：US20140057916A1

  公开（公告）日：2014-02-27

  This invention relates to substituted 4-pyridones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.

  本发明涉及公式1的取代4-吡啶酮及其作为嗜中性粒细胞弹性蛋白酶活性抑制剂的使用，包含它们的制药组合物，以及将其作为治疗和/或预防肺部、胃肠道和泌尿系统疾病、皮肤和眼睛的炎症性疾病以及其他自身免疫和过敏性疾病、移植排斥和肿瘤性疾病的药剂使用的方法。
• Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
  申请人：Oost Thorsten

  公开号：US09102624B2

  公开（公告）日：2015-08-11

  This invention relates to substituted 4-pyridones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.

  本发明涉及式1的取代4-吡啶酮及其用作中性粒细胞弹性蛋白酶活性抑制剂，包含它们的制药组合物以及将其用作治疗和/或预防肺部、胃肠道和泌尿生殖系统疾病、皮肤和眼睛的炎症性疾病、其他自身免疫和过敏性疾病、移植排斥和肿瘤性疾病的药物的方法。
• Cyclic Ether Pyrazol-4-YL-Heterocyclyl-Carboxamide Compounds And Methods Of Use
  申请人：Genentech, Inc.

  公开号：US20160213652A1

  公开（公告）日：2016-07-28

  Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R 2 is a cyclic ether and X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式I中的环氧杂环基卡氧酰胺化合物，包括立体异构体、几何异构体、互变异构体和其药学上可接受的盐，其中R2是环氧杂环基，X是噻唑基、吡嗪基、吡啶基或嘧啶基，可用于抑制Pim激酶，并用于治疗由Pim激酶介导的癌症等疾病。公开了使用公式I中的化合物进行哺乳动物细胞中的体外、原位和体内诊断、预防或治疗此类疾病或相关病理条件的方法。
• Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
  申请人：Genentech, Inc.

  公开号：US09328106B2

  公开（公告）日：2016-05-03

  Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R2 is a cyclic ether and X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式I中的环氧杂环基羧酰胺化合物，包括立体异构体、几何异构体、互变异构体和其药学上可接受的盐，其中R2是一个环氧杂环基，X是噻唑基、吡嗪基、吡啶基或嘧啶基，用于抑制Pim激酶，并用于治疗由Pim激酶介导的癌症等疾病。本文介绍了利用公式I中的化合物在哺乳动物细胞中进行体外、原位和体内诊断、预防或治疗此类疾病或相关病理条件的方法。
• Discovery, Optimization, and Biological Evaluation of 5-(2-(Trifluoromethyl)phenyl)indazoles as a Novel Class of Transient Receptor Potential A1 (TRPA1) Antagonists
  作者：Lisa Rooney、Agnès Vidal、Anne-Marie D’Souza、Nick Devereux、Brian Masick、Valerie Boissel、Ryan West、Victoria Head、Rowan Stringer、Jianmin Lao、Matt J. Petrus、Ardem Patapoutian、Mark Nash、Natalie Stoakley、Moh Panesar、J. Martin Verkuyl、Andrew M. Schumacher、H. Michael Petrassi、David C. Tully

  DOI：10.1021/jm401986p

  日期：2014.6.26

  A high throughput screening campaign identified 5-(2-chlorophenyl)indazole compound 4 as an antagonist of the transient receptor potential A1 (TRPA1) ion channel with IC50 = 1.23 μM. Hit to lead medicinal chemistry optimization established the SAR around the indazole ring system, demonstrating that a trifluoromethyl group at the 2-position of the phenyl ring in combination with various substituents at the 6-position of the indazole ring greatly contributed to improvements in vitro activity. Further lead optimization resulted in the identification of compound 31, a potent and selective antagonist of TRPA1 in vitro (IC50 = 0.015 μM), which has moderate oral bioavailability in rodents and demonstrates robust activity in vivo in several rodent models of inflammatory pain.